{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:37:46Z","timestamp":1788881866265,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T00:00:00Z","timestamp":1592611200000},"content-version":"am","delay-in-days":355,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jconrel.2019.06.003","type":"journal-article","created":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T02:45:56Z","timestamp":1559616356000},"page":"165-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"special_numbering":"C","title":["Formulation and preclinical evaluation of a toll-like receptor 7\/8 agonist as an anti-tumoral immunomodulator"],"prefix":"10.1016","volume":"306","author":[{"given":"Ruolin","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Groer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Kleindl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Ryan","family":"Moulder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aric","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan R.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Aires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory","family":"Berkland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0288-6138","authenticated-orcid":false,"given":"M. Laird","family":"Forrest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2019.06.003_bb0005","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1473-3099(07)70185-8","article-title":"Innate immunogenetics: a tool for exploring new frontiers of host defence","volume":"7","author":"Bochud","year":"2007","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0010","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.bbrc.2009.08.062","article-title":"Toll-like receptors and innate immunity","volume":"388","author":"Kumar","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0015","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0020","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00262-009-0721-8","article-title":"The Toll-like receptor 7\/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells","volume":"59","author":"Smits","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0025","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1128\/AAC.49.10.3991-3996.2005","article-title":"From the Th1\/Th2 Paradigm towards a Toll-Like Receptor\/T-Helper bias","volume":"49","author":"Netea","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0030","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/00003495-199958020-00017","article-title":"Topical Imiquimod","volume":"58","author":"Perry","year":"1999","journal-title":"Drugs."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0035","author":"European Medicines Agency"},{"key":"10.1016\/j.jconrel.2019.06.003_bb0040","doi-asserted-by":"crossref","first-page":"7119","DOI":"10.1158\/1078-0432.CCR-07-1443","article-title":"First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer","volume":"13","author":"Dudek","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0045","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1016\/j.vaccine.2011.05.061","article-title":"Vaccine adjuvant activity of 3m-052: An imidazoquinoline designed for local activity without systemic cytokine induction","volume":"29","author":"Smirnov","year":"2011","journal-title":"Vaccine."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0050","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/blood-2012-05-432393","article-title":"Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma","volume":"121","author":"Dovedi","year":"2013","journal-title":"Blood."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0055","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.vaccine.2018.01.077","article-title":"Routing dependent immune responses after experimental R848-adjuvated vaccination","volume":"36","author":"van Aalst","year":"2018","journal-title":"Vaccine."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0060","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1016\/j.vaccine.2014.02.027","article-title":"Adjuvant-carrying synthetic vaccine particles augment the immune response to encapsulated antigen and exhibit strong local immune activation without inducing systemic cytokine release","volume":"32","author":"Ilyinskii","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2019.06.003_bb0065","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jconrel.2016.11.011","article-title":"Adsorption of a synthetic TLR7\/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: a formulation approach","volume":"244","author":"Fox","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2019.06.003_bb0070","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jconrel.2009.09.010","article-title":"Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives","volume":"141","author":"Oh","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2019.06.003_bb0075","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1021\/acs.bioconjchem.8b00386","article-title":"Hyaluronic acid conjugates of TLR7\/8 agonists for targeted delivery to secondary lymphoid tissue","volume":"29","author":"Yoo","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0080","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.carbpol.2012.08.066","article-title":"Modification and cross-linking parameters in hyaluronic acid hydrogels\u2014definitions and analytical methods","volume":"91","author":"Kenne","year":"2013","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0085","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ijpharm.2004.05.016","article-title":"Nano-emulsion formulation using spontaneous emulsification: solvent, oil and surfactant optimisation","volume":"280","author":"Bouchemal","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0090","author":"Invivogen"},{"key":"10.1016\/j.jconrel.2019.06.003_bb0095","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/BF00046339","article-title":"Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment","volume":"9","author":"MacEwen","year":"1990","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0100","doi-asserted-by":"crossref","first-page":"534","DOI":"10.4161\/hv.23232","article-title":"Immunotherapy in new pre-clinical models of HPV-associated oral cancers","volume":"9","author":"Paolini","year":"2013","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0105","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1288\/00005537-199510000-00013","article-title":"A murine model for the immunotherapy of head and neck squamous cell carcinoma","volume":"105","author":"Hier","year":"1995","journal-title":"Laryngoscope."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0110","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/jso.2930310402","article-title":"Tumor measurement in the nude mouse","volume":"31","author":"Euhus","year":"1986","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0115","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/BF00300234","article-title":"Determination of subcutaneous tumor size in athymic (nude) mice","volume":"24","author":"Tomayko","year":"1989","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0120","doi-asserted-by":"crossref","first-page":"3856 LP","DOI":"10.1158\/1078-0432.CCR-08-1860","article-title":"Multi-center, placebo-controlled, double-blind, randomized study of Oral Toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision","volume":"15","author":"London","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0125","author":"Sample Size Calculator"},{"key":"10.1016\/j.jconrel.2019.06.003_bb0130","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.2174\/092986708785132997","article-title":"Recent trends in targeted anticancer prodrug and conjugate design","volume":"15","author":"Singh","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0135","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1039\/C3PY01384G","article-title":"Recent trends in the design of anticancer polymer prodrug nanocarriers","volume":"5","author":"Delplace","year":"2014","journal-title":"Polym. Chem."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0140","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1080\/07315724.2003.10719283","article-title":"\u03b1-Tocopheryl succinate, the Most effective form of vitamin E for adjuvant Cancer treatment: a review","volume":"22","author":"Prasad","year":"2003","journal-title":"J. Am. Coll. Nutr."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0145","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jconrel.2014.03.009","article-title":"Vitamin E-based nanomedicines for anti-cancer drug delivery","volume":"182","author":"Duhem","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2019.06.003_bb0150","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1021\/acs.molpharmaceut.6b00069","article-title":"Hyaluronic acid molecular weight determines lung clearance and biodistribution after instillation","volume":"13","author":"Kuehl","year":"2016","journal-title":"Mol. Pharm. Pharm."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0155","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1039\/b900456d","article-title":"Self-assembled hyaluronic acid nanoparticles as a potential drug carrier for cancer therapy: synthesis, characterization, and in vivo biodistribution","volume":"19","author":"Choi","year":"2009","journal-title":"J. Mater. Chem."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0160","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.3390\/molecules16032658","article-title":"Investigation of solvolysis kinetics of new synthesized fluocinolone acetonide C-21 esters-an in vitro model for prodrug activation","volume":"16","author":"Markovic","year":"2011","journal-title":"Molecules."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0165","article-title":"Programmed hydrolysis in designing paclitaxel prodrug for nanocarrier assembly","volume":"5","author":"Fu","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0170","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1021\/jm100358c","article-title":"Structure-activity relationships in human toll-like receptor 7-active imidazoquinoline analogues","volume":"53","author":"Shukla","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0175","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1232219","article-title":"Reprogramming of TLR7 signaling enhances antitumor NK and cytotoxic T cell responses","volume":"5","author":"Hotz","year":"2016","journal-title":"Oncoimmunology."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0180","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.4049\/jimmunol.1401160","article-title":"Effective innate and adaptive antimelanoma immunity through localized TLR7\/8 activation","volume":"193","author":"Singh","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0185","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/biof.5520070104","article-title":"Inhibition of NF- \u03baB transcriptional activity by \u03b1-tocopheryl succinate","volume":"7","author":"Nakamura","year":"1998","journal-title":"BioFactors."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0190","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1006\/bbrc.1993.1620","article-title":"Inhibition of NF-\u03baB activation by vitamin E derivatives","volume":"193","author":"Suzuki","year":"1993","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0195","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1191\/0960327102ht286oa","article-title":"Overview of immune system development in the dog: comparison with humans","volume":"21","author":"Felsburg","year":"2002","journal-title":"Hum. Exp. Toxicol."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0200","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.xphs.2017.04.041","article-title":"Thermosensitive gel\u2013based formulation for intratumoral delivery of toll-like receptor 7\/8 dual agonist, MEDI9197","volume":"106","author":"Fakhari","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0205","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-14655-8","article-title":"Development of a curative therapeutic vaccine (TheraVac) for the treatment of large established tumors","volume":"7","author":"Nie","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0210","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93397","article-title":"Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer","volume":"2","author":"Sato-Kaneko","year":"2017","journal-title":"JCI Insight."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0215","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1200\/JCO.2006.07.9129","article-title":"Phase II trial of a toll-like receptor 9\u2013activating oligonucleotide in patients with metastatic melanoma","volume":"24","author":"Pashenkov","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2019.06.003_bb0220","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154253","article-title":"Expression of CD11c is associated with unconventional activated T cell subsets with high migratory potential","volume":"11","author":"Qualai","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2019.06.003_bb0225","first-page":"606","article-title":"Increase of regulatory T cells in the peripheral blood of cancer patients","volume":"9","author":"Wolf","year":"2003","journal-title":"Clin. Cancer Res."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836591930313X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836591930313X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:40:25Z","timestamp":1759160425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836591930313X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":45,"alternative-id":["S016836591930313X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2019.06.003","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Formulation and preclinical evaluation of a toll-like receptor 7\/8 agonist as an anti-tumoral immunomodulator","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2019.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}